In conclusion, consistent with previously published preclinical experiments that support the inhibition of Wnt signaling as a potential mechanism for hindering tumor cell growth, tumor survival, and metastasis, in the current study we show that sclerostin, a Wnt antagonist, has the potential to inhibit prostate cancer invasion, in vitro, and to reduce the incidence of macroscopic metastases and osteolysis in NSG mice, in vivo. The gene discussed is SOST; the disease is prostate carcinoma.